BeOne strengthens its BTK position at ASH 

BeOne is defending Brukinsa’s recently earned position as the top-selling BTK inhibitor with long-term data showing nearly three-quarters of treatment-naive CLL patients remain progression-free at six years. The company is parlaying the program’s success into a broader strategy, using BTK as the entry point for a protein degrader platform.

At the American Society of Hematology annual meeting, BeOne Medicines Ltd. (NASDAQ:ONC; HKEX:06160; Shanghai:688235) presented data from a pair of Phase III studies of Brukinsa zanubrutinib that build the case for long-term safety and efficacy both in first-line and relapsed settings — features particularly important in the chronic form of leukemia. ...